Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
fluticasone propionate DISKUS · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| fluticasone propionate/salmeterol 250/50 DISKUS combination product | DRUG | - |
| fluticasone propionate DISKUS 500mcg | DRUG | - |
Inclusion criteria: * Established history of chronic obstructive pulmonary disease (COPD). * Lung function parameters: FEV1/FVC ratio \< 70%, FEV1 between 80% and 30% predicted, a reversibility of airway obstruction of 12% of the initial value with a minimum of 200 mL. * Signed and dated informed c...
Fluticasone propionate DISKUS is used for the treatment of partial reversible Chronic Obstructive Pulmonary Disease (COPD). It is a small molecule developed by GSK plc for the respiratory therapeutic area. The drug is delivered via the DISKUS inhalation device and is currently in Phase 3 clinical development.
Fluticasone propionate DISKUS is a corticosteroid that works by reducing inflammation in the airways. It is used in the treatment of Chronic Obstructive Pulmonary Disease (COPD) to help improve lung function and manage symptoms. The drug is administered through the DISKUS dry powder inhaler.
Fluticasone propionate DISKUS is developed by GSK plc, a global biopharma company listed on the stock exchange under the ticker GSK. The drug is being investigated for the treatment of Chronic Obstructive Pulmonary Disease (COPD) and is currently in Phase 3 clinical trials.
Fluticasone propionate DISKUS is in Phase 3 clinical development for the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is an investigational drug and has not been approved by regulatory authorities. One Phase 3 trial has been completed with 290 participants enrolled.
Fluticasone propionate DISKUS has one completed Phase 3 clinical trial registered under NCT00549146. The trial, titled 'Treatment Of Partial Reversible Chronic Obstructive Pulmonary Disease', enrolled 290 participants in the Netherlands. It was a randomized, double-blind study without a control group, involving patients aged 40 years and older.
Fluticasone propionate DISKUS is a specific formulation of fluticasone propionate delivered via the DISKUS dry powder inhaler device. The DISKUS version is designed for inhalation in the treatment of Chronic Obstructive Pulmonary Disease (COPD). It is developed by GSK plc and is currently in Phase 3 clinical trials.